Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lifeward Ltd. (LFWD)

Lifeward names Ronen Tsimerman chief financial officer effective November 1, 2026

Neutral Impact 3 of 5 leadership Written later

Lifeward Ltd. said its Board appointed Ronen Tsimerman as chief financial officer, principal financial officer and principal accounting officer, effective November 1, 2026. The filing describes his prior CFO roles at IceCure Medical, Insuline Medical and Mer-Group, and his pay terms are tied to shareholder approval of a renewed compensation policy at the October 30, 2026 annual meeting.

Key points

  • Appointed by the Board on October 26, 2026; effective November 1, 2026
  • Gross monthly base salary of NIS 70,000, plus an annual performance-based bonus with a target of not less than four monthly salaries
  • Three-month termination notice, rising to four months for either party after a change in the CEO

The filing

CompanyLifeward Ltd. (LFWD)
Form8-K, current report
Filed with the SECOct 27, 2026, 8:55 AM ET
Accession number0001178913-26-004856

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.